ID   LA-N-2
AC   CVCL_1829
SY   LAN-2; LAN2
DR   CLO; CLO_0050262
DR   BioSample; SAMN03472328
DR   BioSample; SAMN03473426
DR   cancercelllines; CVCL_1829
DR   Cell_Model_Passport; SIDM01370
DR   Cosmic; 801741
DR   Cosmic; 920241
DR   Cosmic; 947711
DR   Cosmic; 1037344
DR   Cosmic; 1099141
DR   Cosmic; 1109103
DR   Cosmic; 1153782
DR   Cosmic; 1526628
DR   Cosmic; 2131579
DR   Cosmic; 2301575
DR   Cosmic; 2485947
DR   DepMap; ACH-001354
DR   DSMZ; ACC-671
DR   DSMZCellDive; ACC-671
DR   ECACC; 06041202
DR   GEO; GSM313803
DR   GEO; GSM333798
DR   Lonza; 1195
DR   Progenetix; CVCL_1829
DR   RCB; RCB0484
DR   Wikidata; Q54901876
RX   DOI=10.1007/0-306-46872-7_2;
RX   PubMed=856461;
RX   PubMed=7037175;
RX   PubMed=15720811;
RX   PubMed=18923524;
RX   PubMed=24466371;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Characteristics: Intermediate type (I-type) (PubMed=15720811).
CC   Doubling time: ~50-70 hours (Note=But longer after recovery from liquid nitrogen freezing) (DSMZ=ACC-671).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg337Cys (c.1009C>T); ClinVar=VCV000142536; Zygosity=Unspecified (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
ST   Source(s): COG; DepMap; DSMZ; ECACC; RCB
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11,12
ST   D16S539: 9,10
ST   D18S51: 15,18
ST   D19S433: 14
ST   D21S11: 29,30
ST   D2S1338: 20
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 8,10
ST   D8S1179: 13,15
ST   FGA: 20,22
ST   Penta D: 11,12
ST   Penta E: 11,17
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   3Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 25
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   PubMed=856461;
RA   Seeger R.C., Rayner S.A., Banerjee A., Chung H., Laug W.E.,
RA   Neustein H.B., Benedict W.F.;
RT   "Morphology, growth, chromosomal pattern and fibrinolytic activity of
RT   two new human neuroblastoma cell lines.";
RL   Cancer Res. 37:1364-1371(1977).
//
RX   PubMed=7037175;
RA   Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.;
RT   "Selective toxicity of 6-hydroxydopamine and ascorbate for human
RT   neuroblastoma in vitro: a model for clearing marrow prior to
RT   autologous transplant.";
RL   Cancer Res. 42:1331-1336(1982).
//
RX   PubMed=15720811; DOI=10.1593/neo.04310;
RA   Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F.,
RA   Biedler J.L., Cheung N.-K.V., Ross R.A.;
RT   "Characteristics of stem cells from human neuroblastoma cell lines and
RT   in tumors.";
RL   Neoplasia 6:838-845(2004).
//
RX   PubMed=18923524; DOI=10.1038/nature07399;
RA   Chen Y.-Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M.,
RA   Wang L.-L., Soda M., Kikuchi A., Igarashi T., Nakagawara A.,
RA   Hayashi Y., Mano H., Ogawa S.;
RT   "Oncogenic mutations of ALK kinase in neuroblastoma.";
RL   Nature 455:971-974(2008).
//
RX   PubMed=24466371; DOI=10.1593/tlo.13544;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
//